Actively Recruiting
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Led by Bruyère Health Research Institute. · Updated on 2025-04-15
50
Participants Needed
3
Research Sites
113 weeks
Total Duration
On this page
Sponsors
B
Bruyère Health Research Institute.
Lead Sponsor
T
The Ottawa Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg/kg/hour, titrated up to 1.0 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.
CONDITIONS
Official Title
Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Admitted to a participating inpatient palliative care unit
- Have agitated delirium with a Richmond Agitation-Sedation Scale for palliative care patients (RASS-PAL) score of +2 or greater and positive Confusion Assessment Method (CAM) status, without a known reversible cause or with a decision not to treat the cause
- Or have a previous history of delirium in the last 6 months
- Or are within the last two weeks of life and expected to die during this admission as judged by the medical responsible practitioner
You will not qualify if you...
- Hemodynamic instability with systolic blood pressure less than 80 mmHg
- Bradyarrhythmia with heart rate less than 60 beats per minute at baseline
- Current use of verapamil, diltiazem, or beta-blocker medications unless stopped before receiving dexmedetomidine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Foothills Medical Centre
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
2
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
3
Bruyère Continuing Care
Ottawa, Ontario, Canada, K1N 5C8
Actively Recruiting
Research Team
J
James Downar, MDCM, MSc
CONTACT
J
Julie Lapenskie, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here